典型文献
First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial
文献摘要：
Objective: To examine the efficacy and safety of anlotinib as first-line therapy to treat locally advanced or metastatic soft-tissue sarcoma.Methods: This is a single-arm trial. Treatment-na?ve patients (≥14 years) with locally advanced or metastatic soft tissue sarcoma were eligible. Each treatment cycle lasted for 3 weeks, and included liposomal doxorubicin (40-50 mg/m2) on day 1 and anlotinib (12 mg) on days 8-21. Starting from the 9th cycle, treatment consisted of only anlotinib. Treatment continued until disease progression or intolerable toxicities. The primary efficacy end point was progression-free survival (PFS). Results: Eight patients were enrolled between July 25, 2019 and January 8, 2020. The median number of treatment cycles was 5.5. Within 5.9 months median follow-up, PFS events occurred in 4 (4/8, 50％) patients. The median PFS was 11.3 months and the 6-month PFS rate was 56％. No patients attained complete response and 2 patients (fibrosarcoma, 1 patient and undifferentiated pleomorphic sarcoma, 1 patient) achieved partial response. Three patients (fibrosarcoma, 2 patients and synovial sarcoma, 1 patient) had stable disease. The objective response rate was 25％ (2/8) for the study population, and the disease control rate was 75％ (6/8). No new safety concerns emerged. Conclusions: Anlotinib plus liposomal doxorubicin demonstrated antitumor activities in previously untreated locally advanced or metastatic soft tissue sarcomas. Due to the small sample size, further investigations with a larger population should be undertaken to confirm the study findings.
文献关键词：
中图分类号：
作者姓名：
Xin Sun;Ranxin Zhang;Jie Xu;Lu Xie;Wei Guo
作者机构：
Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China
文献出处：
引用格式：
[1]Xin Sun;Ranxin Zhang;Jie Xu;Lu Xie;Wei Guo-.First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial)[J].亚太热带医药杂志（英文版）,2022(06):266-273
A类：
B类：
First,line,anlotinib,plus,liposomal,doxorubicin,locally,advanced,metastatic,soft,tissue,prospective,single,arm,trial,Objective,To,examine,efficacy,safety,first,therapy,Methods,This,Treatment,na,patients,years,were,eligible,Each,treatment,lasted,weeks,included,days,Starting,from,9th,consisted,only,continued,until,disease,progression,intolerable,toxicities,primary,end,point,was,free,survival,PFS,Results,Eight,enrolled,between,July,January,median,number,cycles,Within,months,follow,up,events,occurred,No,attained,complete,response,fibrosarcoma,undifferentiated,pleomorphic,achieved,partial,Three,synovial,had,stable,objective,study,population,control,new,concerns,emerged,Conclusions,Anlotinib,demonstrated,antitumor,activities,previously,untreated,sarcomas,Due,small,sample,size,further,investigations,larger,should,undertaken,confirm,findings
AB值：
0.52859
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
